Device Trial Radar · NCT03215914
Hybrid Closed Loop Insulin Delivery System in Hypoglycemia
Last checked: Nov 20, 2026Latest source record: Oct 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Aug 1, 2017
Primary completion
May 31, 2022
Study completion Oct 1, 2024
Sponsor
- Lead sponsor
- University of PennsylvaniaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- First posted
- Jul 12, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 25 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Can a type 1 diabetic adult avoid low glucoses and regain hypoglycemia awareness using a hybrid closed loop insulin delivery system? Involvement is 22 months (13 visits) and includes a 4-week Screening Phase and an 18-month Intervention Phase. Participants will undergo 3 Hyperinsulinemic Clamps done at: Baseline (before starting the device and after completing the screening), 6 months (after using the device 6 months), and after using the device for 18 months. This metabolic testing will allow us to measure improvement in hypoglycemia awareness.
Conditions
- Type1diabetes
- Hypoglycemia Unawareness
- Nocturnal Hypoglycemia
- Hypoglycemia Night
- Hypoglycemia
Interventions
MiniMed 670G systemDevice
Eligible subjects with type 1 diabetes will initiate hybrid closed-loop insulin delivery based on interstitial glucose monitoring via the MiniMed 670G system according to Medtronic's labeling. This system combines subject-delivered pre-meal boluses with automatic interprandial insulin delivery that includes automated functions for both predictive and threshold suspension of insulin delivery intended to minimize exposure to glucose levels \< 70 mg/dl.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Endogenous Glucose ProductionTime frame: After 6 months of hybrid closed-loop insulin delivery.
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Clinical and Translational Research Center, Hospital of University of Pennsylvania
Philadelphia, Pennsylvania
Rodebaugh Diabetes Center, University of Pennsylvania
Philadelphia, Pennsylvania
University of Pennsylvania - Institute for Diabetes, Obesity and Metabolism
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.